Gary Wilkinson

1.1k total citations
23 papers, 546 citations indexed

About

Gary Wilkinson is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gary Wilkinson has authored 23 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gary Wilkinson's work include DNA Repair Mechanisms (5 papers), Cancer therapeutics and mechanisms (3 papers) and Cancer-related Molecular Pathways (3 papers). Gary Wilkinson is often cited by papers focused on DNA Repair Mechanisms (5 papers), Cancer therapeutics and mechanisms (3 papers) and Cancer-related Molecular Pathways (3 papers). Gary Wilkinson collaborates with scholars based in United Kingdom, United States and Germany. Gary Wilkinson's co-authors include Sylvie M. Guichard, Rajesh Odedra, Christine Wood, Kevin M. Foote, Kevin Blades, Philip J. Jewsbury, Paul Turner, James Yates, Thomas M. McGuire and Dan Heathcote and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Gary Wilkinson

21 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Wilkinson United Kingdom	10	327	179	125	78	55	23	546
Benjamin F. Chu United States	8	209 0.6×	241 1.3×	48 0.4×	62 0.8×	68 1.2×	8	517
Douglas W. Beight United States	10	392 1.2×	210 1.2×	143 1.1×	34 0.4×	41 0.7×	15	616
Alexis de Haven Brandon United Kingdom	12	424 1.3×	179 1.0×	70 0.6×	81 1.0×	32 0.6×	22	595
Toshiaki Tsunenari United States	15	189 0.6×	175 1.0×	92 0.7×	90 1.2×	45 0.8×	27	513
Yibin Zeng United States	15	208 0.6×	111 0.6×	416 3.3×	70 0.9×	44 0.8×	25	768
Khalid Benbatoul United States	10	284 0.9×	232 1.3×	116 0.9×	19 0.2×	17 0.3×	25	564
Naoto Ohi Japan	12	276 0.8×	169 0.9×	86 0.7×	30 0.4×	30 0.5×	19	519
William T. McMillen United States	9	412 1.3×	212 1.2×	95 0.8×	36 0.5×	17 0.3×	15	585
Angela Hayes United Kingdom	15	484 1.5×	259 1.4×	75 0.6×	69 0.9×	42 0.8×	33	659
Qiuping Xiang China	12	407 1.2×	118 0.7×	97 0.8×	105 1.3×	133 2.4×	28	623

Countries citing papers authored by Gary Wilkinson

Since Specialization

Citations

This map shows the geographic impact of Gary Wilkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Wilkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Wilkinson more than expected).

Fields of papers citing papers by Gary Wilkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Wilkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Wilkinson. The network helps show where Gary Wilkinson may publish in the future.

Co-authorship network of co-authors of Gary Wilkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Wilkinson. A scholar is included among the top collaborators of Gary Wilkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Wilkinson. Gary Wilkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papadopoulos, Kyriakos P., Meredith McKean, Silvia Goldoni, et al.. (2024). First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A. Clinical Cancer Research. 30(24). 5568–5576. 3 indexed citations

Falkowski, Adam, Milena Mazan, Agnieszka Szymula, et al.. (2024). Trial in Progress: An Open-Label Clinical Trial of RVU120 As Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61). Blood. 144(Supplement 1). 6632–6632.

Papayannidis, Cristina, Krzysztof Mądry, Witold Prejzner, et al.. (2024). River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia. Blood. 144(Supplement 1). 6005–6005.

Wengner, Antje M., et al.. (2022). Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models. European Journal of Cancer. 174. S101–S101. 3 indexed citations

Yap, Timothy A., David S.P. Tan, Anastasios Stathis, et al.. (2022). Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects. Cancer Research. 82(12_Supplement). CT006–CT006. 8 indexed citations

Zurth, Christian, Pirjo Nykänen, Gary Wilkinson, et al.. (2021). Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. Clinical Pharmacokinetics. 61(4). 565–575. 10 indexed citations

Zurth, Christian, Mikko Koskinen, Robert E. Fricke, et al.. (2019). Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. European Journal of Drug Metabolism and Pharmacokinetics. 44(6). 747–759. 71 indexed citations

Postel‐Vinay, Sophie, Karin H. Herbschleb, Christophe Massard, et al.. (2019). First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. European Journal of Cancer. 109. 103–110. 70 indexed citations

Schneeweiß, Andreas, Dagmar Hess, Markus Joerger, et al.. (2019). Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers. 11(12). 1987–1987. 10 indexed citations

10.

Zurth, Christian, Karsten Denner, Timo Korjamo, et al.. (2019). Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.. Journal of Clinical Oncology. 37(7_suppl). 297–297. 9 indexed citations

11.

Schneeweiß, Andreas, Markus Joerger, Andréa Varga, et al.. (2019). Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer. Cancer Research. 79(13_Supplement). CT015–CT015. 1 indexed citations

12.

Bono, Johann S. de, David S.P. Tan, Reece Caldwell, et al.. (2019). First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3007–3007. 25 indexed citations

13.

Foote, Kevin M., J. Willem M. Nissink, Thomas M. McGuire, et al.. (2018). Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. Journal of Medicinal Chemistry. 61(22). 9889–9907. 225 indexed citations

14.

Waring, Michael J., Scott Boyd, Leonie Campbell, et al.. (2013). Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets – the discovery of AZD3651 and AZD9485. MedChemComm. 4(4). 663–663. 6 indexed citations

15.

Baker, David, et al.. (2013). Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes. British Journal of Pharmacology. 171(7). 1629–1641. 9 indexed citations

16.

Jones, Clifford D., Kevin Blades, Kevin M. Foote, et al.. (2013). Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.. Cancer Research. 73(8_Supplement). 2348–2348. 29 indexed citations

17.

Waring, Michael J., Scott Boyd, Leonie Campbell, et al.. (2013). Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content. MedChemComm. 4(4). 657–657. 6 indexed citations

18.

Baker, David, et al.. (2013). Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. British Journal of Pharmacology. 171(7). 1642–1654. 9 indexed citations

19.

Wilkinson, Gary, James P. Taylor, Steven D. Shnyder, et al.. (2004). Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. Investigational New Drugs. 22(3). 231–240. 18 indexed citations

20.

Wilkinson, Gary. (1951). The use of gold as a therapeutic agent in small-animal practice. Veterinary Record. 63(7). 127–129. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact